Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

(2020) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

(2020) Joshua D. Hansen et al.   JOURNAL OF MEDICINAL CHEMISTRY

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

(2020) Lijie Xing et al.   LEUKEMIA

Immunotherapy of multiple myeloma

(2020) Simone A. Minnie et al.   JOURNAL OF CLINICAL INVESTIGATION

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma

(2020) Nisha S. Joseph et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways

(2020) Teru Hideshima et al.   LEUKEMIA

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies

(2020) Margaux Lejeune et al.   Frontiers in Immunology

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

(2020) Maria-Victoria Mateos et al.   Lancet Haematology

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma

(2020) Hideto Tamura et al.   Cancers

Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance

(2020) Lisa C. Holthof et al.   Cancers

Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance

(2020) Matthew Ho et al.   Clinical Lymphoma Myeloma & Leukemia

Multiple myeloma: the (r)evolution of current therapy and a glance into future

(2020) Annamaria Gulla et al.   HAEMATOLOGICA

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma

(2020) Estefanía García-Guerrero et al.   Frontiers in Immunology

BCMA-targeted immunotherapy for multiple myeloma

(2020) Bo Yu et al.   Journal of Hematology & Oncology

The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models

(2020) Shih-Feng Cho et al.   Blood Advances

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

(2019) Suzanne Trudel et al.   Blood Cancer Journal

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

(2019) Jooeun Bae et al.   LEUKEMIA

The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa

(2019) Laura Moreno et al.   CLINICAL CANCER RESEARCH

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE ‐013

(2019) Vincent Ribrag et al.   BRITISH JOURNAL OF HAEMATOLOGY

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

(2019) Thierry Facon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

(2019) Philippe Moreau et al.   LANCET

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

(2019) Paul G Richardson et al.   LANCET ONCOLOGY

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor

(2019) Mingpeng Fu et al.   Frontiers in Immunology

The future of checkpoint inhibition in multiple myeloma?

(2019) Caitlin Costello   Lancet Haematology

γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

(2019) Margot J. Pont et al.   BLOOD

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity

(2019) Arghya Ray et al.   Blood Cancer Journal

How to Train your T cells: Overcoming Immune Dysfunction in Multiple Myeloma

(2019) Adam D Cohen et al.   CLINICAL CANCER RESEARCH

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

(2019) Chad C. Bjorklund et al.   LEUKEMIA

Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?

(2019) Mattia D’Agostino et al.   LEUKEMIA

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

(2019) Michel Attal et al.   LANCET

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

(2018) Elizabeth K. O'Donnell et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunopathogenesis and immunotherapy of multiple myeloma

(2018) Hideto Tamura   INTERNATIONAL JOURNAL OF HEMATOLOGY

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

(2018) Jooeun Bae et al.   LEUKEMIA

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

(2018) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma

(2018) Roberta Ettari et al.   PHARMACOLOGY & THERAPEUTICS

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives

(2018) Remy Thomas et al.   Frontiers in Immunology

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

(2018) Shih-Feng Cho et al.   Frontiers in Immunology

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

(2018) Niels W.C.J. van de Donk et al.   Frontiers in Immunology

Checkpoint Inhibition in Myeloma: Opportunities and Challenges

(2018) Federica Costa et al.   Frontiers in Immunology

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

(2018) Suzanne Trudel et al.   LANCET ONCOLOGY

Melanoma vaccines

(2018) Deena M. Maurer et al.   MELANOMA RESEARCH

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma

(2018) Tomas Jelinek et al.   Frontiers in Immunology

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

(2018) Stefania Oliva et al.   Frontiers in Immunology

Is immunotherapy here to stay in multiple myeloma?

(2017) Paula Rodríguez-Otero et al.   HAEMATOLOGICA

PD-1/PD-L1 inhibitors in haematological malignancies: update 2017

(2017) Tomas Jelinek et al.   IMMUNOLOGY

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

(2017) Brian G M Durie et al.   LANCET

Proteomic characterization of human multiple myeloma bone marrow extracellular matrix

(2017) S V Glavey et al.   LEUKEMIA

Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’

(2017) Matthew Ho Zhi Guang et al.   LEUKEMIA & LYMPHOMA

Is immunotherapy here to stay in multiple myeloma?

(2017) Paula Rodríguez-Otero et al.   HAEMATOLOGICA

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma

(2016) Nicole C. Smits et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

(2016) Larysa Sanchez et al.   Journal of Hematology & Oncology

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

(2016) S Hipp et al.   LEUKEMIA

Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice

(2016) Rituparna Das et al.   NATURE MEDICINE

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases

(2016) Elizabeth E. Hull et al.   Biomed Research International

Cellular and vaccine immunotherapy for multiple myeloma

(2016) A. L. Garfall et al.   Hematology-American Society of Hematology Education Program

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

(2015) Jessica R. McCombs et al.   AAPS Journal

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

(2015) Bruno Paiva et al.   BLOOD

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets

(2015) K. Sehgal et al.   BLOOD

Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study

(2015) Katy J. McCann et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma

(2015) Jianxuan Zou et al.   CANCER SCIENCE

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

(2015) G. Gorgun et al.   CLINICAL CANCER RESEARCH

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

(2015) H Jiang et al.   LEUKEMIA

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

(2015) B Paiva et al.   LEUKEMIA

Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells

(2015) A Ray et al.   LEUKEMIA

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

(2015) Marije B Overdijk et al.   mAbs

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

(2015) Alfred L. Garfall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma

(2015) Kimberly A. Noonan et al.   Science Translational Medicine

γ-secretase directly sheds the survival receptor BCMA from plasma cells

(2015) Sarah A. Laurent et al.   Nature Communications

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

(2014) Aaron P. Rapoport et al.   CLINICAL CANCER RESEARCH

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

(2014) C. Blimark et al.   HAEMATOLOGICA

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

(2014) E M Ocio et al.   LEUKEMIA

A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients

(2014) J Bae et al.   LEUKEMIA

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

(2014) Lotfi Benboubker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

(2013) Anita K. Gandhi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

(2013) Shauna M. Collins et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients

(2013) J. Rosenblatt et al.   CLINICAL CANCER RESEARCH

Toxicity management for patients receiving novel T-cell engaging therapies

(2013) David M. Barrett et al.   CURRENT OPINION IN PEDIATRICS

Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy

(2013) David J Chung et al.   Journal of Translational Medicine

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

(2013) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Human Langerhans cells use an IL-15R- /IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1

(2012) E. Romano et al.   BLOOD

Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

(2012) J. Bae et al.   CLINICAL CANCER RESEARCH

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

(2012) H Tamura et al.   LEUKEMIA

Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade

(2011) William H.D. Hallett et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

(2011) J. A. Zonder et al.   BLOOD

Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study

(2011) S. Y. Kristinsson et al.   HAEMATOLOGICA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

(2010) J. Rosenblatt et al.   BLOOD

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Cellular Vaccine Approaches

(2010) Dung T. Le et al.   CANCER JOURNAL

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

(2009) O. Landgren et al.   BLOOD

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH

Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology

(2008) Fabio Malavasi et al.   PHYSIOLOGICAL REVIEWS

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD